Literature DB >> 17622488

Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation.

Mehmet Polatli1, Aysel Cakir, Orhan Cildag, A Zahit Bolaman, Cigdem Yenisey, Yavuz Yenicerioglu.   

Abstract

In COPD, the systemic effects of the disease reflect the structural and/or biochemical alterations occurring in the structures or organs other than the lungs in relation to the characteristics of the primary disease. The disorders of endothelial structures due to COPD may lead vascular pathologies, such as ischemic heart disease, stroke, to occur more commonly in those with COPD. On consideration of the fact that the vascular endothelium is a major site in which the systemic effect of the inflammation occurs, should von Willebrand Factor, a clotting factor of endothelium origin, and the plasma level of fibrinogen vary with the severity of the disease in COPD, the variability of arterial blood gas values, and the stability or exacerbation of the disease? Considering the fact that microalbuminuria is an indirect manifestation of the renal endothelial permeability and/or renal perfusion; should there be an association between microalbuminuria and the severity of COPD? Therefore, in order to assess the effect of the systemic inflammation in COPD on the vascular endothelium, we compared the levels of the plasma vWF, fibrinogen, 24-h urine microalbuminuria of those with stable COPD (33 patients) and exacerbation of COPD (26 patients) with those of the controls (16 healthy subjects). The mean age was 63.42 -/+ 10.29, 68.00 -/+ 9.77 and 59.63 -/+ 14.10 years in SCOPD, COPDAE, and CG, respectively. The level of microalbuminuria was found to increase significantly in COPDAE group, compared to that of the controls (P = 0.004). When we investigated the relation between smoking burden and microalbuminuria, vWF, fibrinogen levels, the amount of consumption and positive relationship were found significant. (r = 0.336, P = 0.003 between smoking pack-years and vWF, r = 0.403, P = 0.001 between smoking pack-years and fibrinogen, and r = 0.262, P = 0.02 between smoking pack-years and microalbuminuria). The levels of vWF and fibrinogen are AECOPD > SCOPD > CG, with the highest being in AECOPD, and the difference among the groups was statistically significant. The relationship between the level of hypoxemia and microalbuminuria, fibrinogen and vWF was found to be significant (r = -0.360, P = 0.005 between oxygen saturation and microalbuminuria, r = -0.359, P = 0.005 between the level of PaO(2) and fibrinogen, and r = -0.336, P = 0.009 between PaO(2) and vWF). In conclusion, the levels of plasma vWF, fibrinogen, and microalbuminuria may be helpful in grading the severity of COPD exacerbation. The related increase in these markers may represent a possible pathophysiological mechanism behind the increased vascular morbidity of patients with COPD and detecting indirectly the endothelial dysfunction as a manifestation of systemic outcomes due to COPD and in detecting earlier the cases in which the risk for developing the associated complications are higher. We suggest that further studies are necessary to investigate the impact of antithrombotic treatment on microalbuminuria, plasma vWF and fibrinogen as markers of endothelial dysfunction coexisting COPD exacerbation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622488     DOI: 10.1007/s11239-007-0073-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

1.  Proteinuria in COPD patients with and without respiratory failure.

Authors:  Annalisa Cogo; Adalberto Ciaccia; Cristina Legorini; Antonio Grimaldi; GianFranco Milani
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

Review 2.  Endothelial cells in physiology and in the pathophysiology of vascular disorders.

Authors:  D B Cines; E S Pollak; C A Buck; J Loscalzo; G A Zimmerman; R P McEver; J S Pober; T M Wick; B A Konkle; B S Schwartz; E S Barnathan; K R McCrae; B A Hug; A M Schmidt; D M Stern
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

3.  Reversible proteinuria in obstructive sleep apnea syndrome.

Authors:  A H Sklar; B A Chaudhary
Journal:  Arch Intern Med       Date:  1988-01

4.  Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease.

Authors:  T Hirano; K Ookubo; K Kashiwazaki; H Tajima; G Yoshino; M Adachi
Journal:  Clin Chim Acta       Date:  2000-09       Impact factor: 3.786

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

6.  Proteinuria in obstructive sleep apnea.

Authors:  L F Casserly; N Chow; S Ali; D J Gottlieb; L J Epstein; J S Kaufman
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

Review 7.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

8.  Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension.

Authors:  A A Lopes; N Y Maeda; S P Bydlowski
Journal:  Am J Med       Date:  1998-07       Impact factor: 4.965

9.  Plasma levels of von Willebrand factor antigen in acute bronchitis and in a normal population.

Authors:  D A Boldy; P E Short; P Cowen; F G Hill; D C Chambers; J G Ayres
Journal:  Respir Med       Date:  1998-03       Impact factor: 3.415

Review 10.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis.

Authors:  W Q Gan; S F P Man; A Senthilselvan; D D Sin
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

View more
  27 in total

1.  A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

2.  Beclin-1 regulates cigarette smoke-induced kidney injury in a murine model of chronic obstructive pulmonary disease.

Authors:  Maria A Pabón; Edwin Patino; Divya Bhatia; Joselyn Rojas-Quintero; Kevin C Ma; Eli J Finkelsztein; Juan C Osorio; Faryal Malick; Francesca Polverino; Caroline A Owen; Stefan W Ryter; Augustine Mk Choi; Suzanne M Cloonan; Mary E Choi
Journal:  JCI Insight       Date:  2018-09-20

Review 3.  The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema.

Authors:  R Graham Barr
Journal:  Proc Am Thorac Soc       Date:  2011-11

4.  Fibrinogen mediates cadmium-induced macrophage activation and serves as a predictor of cadmium exposure in chronic obstructive pulmonary disease.

Authors:  Fu Jun Li; Ranu Surolia; Pooja Singh; Kevin G Dsouza; Crystal T Stephens; Zheng Wang; Rui-Ming Liu; Sejong Bae; Young-Il Kim; Mohammad Athar; Mark T Dransfield; Veena B Antony
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-02-24       Impact factor: 5.464

5.  Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia.

Authors:  Suba Krishnan; Jamie Siegel; Gene Pullen; Megan Hevelow; Carlton Dampier; Marie Stuart
Journal:  Thromb Res       Date:  2008-01-29       Impact factor: 3.944

6.  Urinary albumin-creatinine ratio, estimated glomerular filtration rate, and all-cause mortality among US adults with obstructive lung function.

Authors:  Earl S Ford
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

Review 7.  Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype.

Authors:  Derek W Russell; J Michael Wells; J Edwin Blalock
Journal:  Curr Opin Pulm Med       Date:  2016-03       Impact factor: 3.155

8.  Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum.

Authors:  Stefan Röpcke; Olaf Holz; Gereon Lauer; Meike Müller; Susanne Rittinghausen; Peter Ernst; Gezim Lahu; Martin Elmlinger; Norbert Krug; Jens M Hohlfeld
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

9.  The association of systemic microvascular changes with lung function and lung density: a cross-sectional study.

Authors:  Bianca Harris; Ronald Klein; Michael Jerosch-Herold; Eric A Hoffman; Firas S Ahmed; David R Jacobs; Barbara E K Klein; Tien Y Wong; Joao A C Lima; Mary Frances Cotch; R Graham Barr
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Von Willebrand factor, ADAMTS13 and mortality in dialysis patients.

Authors:  Gurbey Ocak; Mark Roest; Marianne C Verhaar; Maarten B Rookmaaker; Peter J Blankestijn; Willem Jan W Bos; Rob Fijnheer; Nathalie C Péquériaux; Friedo W Dekker
Journal:  BMC Nephrol       Date:  2021-06-16       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.